menu ☰
menu ˟

FDA accepts IND application for Spero Therapeutics’ investigational antibiotic for cUTIs

06 Feb 2019
Spero Therapeutics announced that the FDA has accepted an investigational new drug application for SPR994, an oral carbapenem antibiotic, for the treatment of complicated UTIs.The acceptance allows Spero to begin enrolling participants from the Unite...

Click here to view the full article which appeared in Nursing

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.